Description

Chrysalin (TP-508) – Research Compound

Disclaimer: This compound is provided strictly for laboratory and scientific research purposes only. It is not approved by the U.S. Food and Drug Administration (FDA) for human or veterinary use, including ingestion, injection, or any form of administration.

Chemical Properties of the Compound

Overview

Chrysalin (TP-508), commonly referred to as rusalatide acetate, is a synthetic 23-amino acid peptide representing the high-affinity receptor-binding domain of human prothrombin  (specifically residues 508–530). It is classified as a nonproteolytic thrombin peptide, meaning that while it binds to a distinct subset of thrombin receptors on fibroblasts, endothelial cells, and stem cells, it does not initiate the proteolytic cleavage cascade associated with thrombin’s role in coagulation. TP-508 is not a SARM, not a hormone analogue, and not a dietary supplement. It is not approved by the FDA for human or veterinary use and is intended strictly for laboratory research purposes.

Working Mechanism of Chrysalin (TP-508)

In preclinical cell culture systems, TP-508 has been investigated as a nonproteolytic agonist at a distinct subset of thrombin receptors. This is expressed on fibroblasts and endothelial cells, where it has been observed to stimulate endothelial nitric oxide synthase (eNOS) activation and rapid NO production. In preclinical animal wound healing models, TP-508 has been observed to stimulate endothelial cell chemokinesis and chemotaxis in a dose-dependent manner, with increased vascularisation markers noted at wound sites in TP-508-treated groups compared to saline controls. In isolated fibroblast cell systems, it has been investigated for its potential to modulate differential gene expression through a nonproteolytic receptor activation pathway, with preclinical data suggesting this may involve upstream signalling events distinct from those initiated by proteolytically active thrombin. Additionally, in vitro studies have examined its potential to affect stem cell proliferation signalling, with data from adipose tissue-derived stem cell cultures suggesting interaction with the PI3K/Akt pathway.

Research Findings / Research Applications

Preclinical investigations have examined Chrysalin (TP-508) in relation to:

In controlled laboratory environments, Chrysalin (TP-508) vials have been investigated for nonproteolytic thrombin receptor binding kinetics and structure-activity relationship (SAR) studies, eNOS activation and nitric oxide signaling pathway research, and as a reference compound in angiogenesis assays using preclinical wound healing models. Research has further examined its role in αvβ3 integrin-mediated signal transduction, fibroblast gene expression pathway investigation, and comparative thrombin fragment pharmacology studies contrasting its nonproteolytic receptor binding profile against proteolytically active thrombin analogs.

Note: These findings are based on early-stage and preclinical research. Results are not consistent across all models, and data remains limited without validation in human clinical settings.

Risks & Handling Information

• The use of appropriate personal protective equipment (PPE) is essential in conducting experiments. Required PPE: nitrile gloves, lab coat, and eye protection at minimum.
• Handling should occur within controlled laboratory environments designed for research activities.
• Do not inhale, ingest, or make direct skin contact with the compound. Avoid inhalation of lyophilized powder during weighing or reconstitution.
• The toxicological profile is not fully established. Exposure risks remain uncertain due to limited long-term safety data. No human safety data has been established for this research-grade formulation.
• Improper storage conditions, including exposure to heat, light, or moisture, may result in compound degradation and compromised sample integrity. The vial seal should remain intact until use.

FAQs

What makes TP-508 nonproteolytic in research contexts?

TP-508 does not activate the proteolytic cleavage cascade associated with thrombin’s coagulation function otherwise. In preclinical settings, it interacts with a distinct receptor subset. This makes it a useful tool for isolating receptor-mediated signaling events in experimental models.

Is Chrysalin (TP-508) safe for human use?

No. Chrysalin (TP-508) is not approved by the FDA for human or veterinary use. Please review the Terms and Conditions before ordering.

What is the vial format for Chrysalin (TP-508) at BC9?

Chrysalin (TP-508) is supplied as a lyophilized powder in a sterile, sealed vial with a flip-top aluminium crimp cap. This format maintains peptide integrity under recommended cold storage conditions. It is the standard for research-grade lyophilized peptides.

References

1. Olszewska-Pazdrak, B., Hart-Vantassell, A., & Carney, D. H. (2010). Thrombin peptide TP508 stimulates rapid nitric oxide production in human endothelial cells. Journal of Vascular Research, 47(3), 203–213. https://pubmed.ncbi.nlm.nih.gov/19893317/
2. Hembrough, T. A., Swartz, G. M., Papathanassiu, A., et al. (2001). Thrombin peptide, TP508, stimulates angiogenic responses in animal models of dermal wound healing, in chick chorioallantoic membranes, and in cultured human aortic and microvascular endothelial cells. Journal of Vascular Research. https://pubmed.ncbi.nlm.nih.gov/11888680/
3. Sower, L. E., Payne, D. A., Meyers, R., & Carney, D. H. (1999). Thrombin peptide, TP508, induces differential gene expression in fibroblasts through a nonproteolytic activation pathway. Experimental Cell Research, 247(2), 422–431. https://pubmed.ncbi.nlm.nih.gov/10066370/
4. Freyberg, S., Song, Y. H., Muehlberg, F., & Alt, E. (2009). Thrombin peptide (TP508) promotes adipose tissue-derived stem cell proliferation via PI3 kinase/Akt pathway. Journal of Vascular Research, 46(2), 98–102. https://pubmed.ncbi.nlm.nih.gov/18607113/

This content is presented exclusively for educational purposes and should not be construed as medical advice. THE MATERIALS REFERENCED HEREIN ARE EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH USE.

Any clinical research initiatives must be conducted under the guidance of the relevant Institutional Review Board (IRB). Similarly, preclinical research involving animals must comply with the directives of the Institutional Animal Care and Use Committee (IACUC), adhering to the standards delineated by the Animal Welfare Act (AWA).

Our informational content is meticulously designed for research-oriented insights and is not a substitute for individual analysis and verification from credible sources before any purchasing decisions are made.

Upon finalizing your order and payment, you explicitly acknowledge and agree to adhere to our Terms and Conditions. Customer satisfaction stands as our paramount concern. If you are dissatisfied with the product received, kindly contact us at 419-707-5450 or email our support team at support@bc9.co.

IMPORTANT NOTICE: All products showcased on our platform are EXCLUSIVELY INTENDED FOR LABORATORY AND RESEARCH APPLICATIONS. They are expressly not intended for veterinary or human utilization.